Related Experiment Video

Updated: Jan 29, 2026

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

1.0K

Hypoglycemic Effects of Oat Oligopeptides in High-Calorie Diet/STZ-Induced Diabetic Rats

Jun-Bo Wang1, Xin-Ran Liu2, Si-Qi Liu3

  • 1Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, China. bmuwjbxy@bjmu.edu.cn.

Molecules (Basel, Switzerland)
|February 6, 2019
PubMed

Insights

Oat oligopeptides (OOPs) show potential in managing type 2 diabetes. This study found OOPs significantly reduced blood glucose and improved key diabetes markers in diabetic rats.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Nutritional Science

Background:

  • Type 2 diabetes mellitus (T2DM) is a significant metabolic disorder characterized by hyperglycemia.
  • Developing effective therapeutic strategies for T2DM remains a critical area of research.
  • Oat-derived compounds are being investigated for their potential health benefits.

Purpose of the Study:

  • To investigate the hypoglycemic effects of oat oligopeptides (OOPs) in a rat model of type 2 diabetes mellitus.
  • To assess the impact of OOPs on glucose metabolism, insulin sensitivity, and oxidative stress.

Main Methods:

  • Type 2 diabetes was induced in Sprague-Dawley rats using a high-calorie diet and streptozotocin injections.
  • Rats were administered varying doses of OOPs (0.25–2.00 g/kg body weight) for 12 weeks.
  • Key metabolic parameters including fasting blood glucose (FBG), oral glucose tolerance test (OGTT), serum insulin, HOMA-IR, antioxidant status (SOD), and hepatic enzymes were measured.

Main Results:

  • Administration of OOPs at 2.00 g/kg significantly decreased FBG and the area under the curve (AUC) of the OGTT.
  • OOPs treatment notably reduced the HOMA-IR index, indicating improved insulin sensitivity.
  • Significant increases in SOD activity and reductions in 24-hour urine volume were observed with OOPs administration.

Conclusions:

  • Oat oligopeptides demonstrate a significant hypoglycemic effect in a rat model of type 2 diabetes.
  • OOPs may serve as a potential therapeutic agent for managing hyperglycemia and improving metabolic profiles in T2DM.
  • Further research is warranted to elucidate the precise mechanisms of action and clinical efficacy of OOPs.
Keywords:
hypoglycemic effectoat oligopeptidesoral glucose tolerance test

More Related Videos

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

7.9K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
655
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
661
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
574
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K